Related Experiment Video
Updated: May 31, 2026
09:38
Direct Reprogramming of Mouse Fibroblasts into Melanocytes
Published on: August 27, 2021
Recombinant human IGF-1 for patients with schizophrenia
1Saint Joseph University, Beirut, Lebanon. ramiboukhalil@hotmail.com
Medical Hypotheses
|June 28, 2011
Summary
Insulin-like Growth Factor-1 (IGF-1) may treat schizophrenia by enhancing brain myelination. Studies show IGF-1 is safe and low levels are linked to schizophrenia, suggesting its potential as a novel therapeutic.
Area of Science:
- Neuroscience
- Endocrinology
- Psychiatry
Background:
- Schizophrenia is characterized by brain connectivity abnormalities, potentially linked to demyelination.
- Low levels of Insulin-like Growth Factor-1 (IGF-1) are observed in patients with schizophrenia.
- IGF-1 plays a crucial role in enhancing myelination via oligodendrocyte stimulation.
Purpose of the Study:
- To explore the potential therapeutic efficacy of IGF-1 in treating schizophrenia.
- To investigate IGF-1 as a treatment for schizophrenia symptoms, particularly in early psychosis.
Main Methods:
- Review of preclinical and clinical data on IGF-1 and demyelinating diseases.
- Analysis of existing evidence regarding IGF-1 levels in schizophrenia patients.
- Proposal of subcutaneous recombinant human IGF-1 (0.05 mg/kg twice daily) based on safety profiles.
Main Results:
- Preclinical data demonstrate IGF-1 enhances myelination.
- Clinical data confirm the safety of IGF-1 in other demyelinating conditions (e.g., multiple sclerosis).
- Evidence suggests IGF-1 administration could be beneficial for schizophrenia symptoms.
Conclusions:
- IGF-1 administration is a potential novel therapeutic strategy for schizophrenia.
- Treatment may be most effective when initiated early, such as in first episode psychosis.
- IGF-1 could serve as an effective adjuvant therapy alongside antipsychotic medications.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:09Recombinant DNA
Overview